20221027104337.jpg)
Yale Cancer Center will join a group of prominent cancer research and treatment institutions in a new Stand Up To Cancer (SU2C) – American Cancer Society $20 million Dream Team to combat lung cancer.
Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.
DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients. A Yale-led comprehensive genomic analysis of more than 700 brain tumors has revealed one such subtype of the most malignant brain tumor, called glioblastoma, or GBM. This subtype possesses thousands of tumor-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival.
Inside the microscopic world of the mouse hair follicle, Yale Cancer Center researchers have discovered big clues about how stem cells regenerate and die. These findings, reported in the journal Nature, could lead to a better understanding of how the stem cell pool is maintained or altered in tissues throughout the body.
A Yale-led team of researchers has developed a new assay, or investigative tool, to measure the anti-tumor immune activity in non-small cell lung cancer tumors that could lead to a more accurate determination of which patients will respond to immune therapy drugs. Findings from the study were published in the Journal of the National Cancer Institute.
A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash prize.
Head and neck squamous cell cancer (HNSCC) ranks among the top ten most prevalent cancers in the United States. Despite its prevalence, little is known about how this cancer develops and spreads. However, in a paper published in the January 29, 2015 edition of Nature, researchers offer critical new information about head and neck cancers.
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal Nature.
Smokers who drink heavily have a tougher time quitting cigarettes than smokers who drink moderately or not at all. However, a multi-center study led by researchers in Yale Cancer Center and Yale School of Medicine found that modifying tobacco-oriented telephone counseling to help hazardous drinkers can help them quit smoking.
A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves. The novel delivery system, described in MicroRNA silencing for cancer therapy targeted to the tumour microenvironment,was published November 17th in the journal Nature.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right